Rubicon's share price stumps research report
A report commissioned by the forestry biotech company suggests Rubicon's share price should be more than double its current level.
The share price of forestry biotech company Rubicon [NZX: RBC] should be “well above current levels,” a research report commissioned by the company says.
An Edison Investment Research report on the company, which was spun out of the old Fletcher Challenge, says the market is undervaluing its two
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Hamish McNicol
Fri, 10 Apr 2015
Fri, 10 Apr 2015
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Rubicon's share price stumps research report
46744